Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1982 Feb;69(2):394–404. doi: 10.1172/JCI110463

Antibody-independent Classical Pathway-mediated Opsonophagocytosis of Type Ia, Group B Streptococcus

Carol J Baker 1,2,3, Morven S Edwards 1,2,3, Bette J Webb 1,2,3, Dennis L Kasper 1,2,3
PMCID: PMC370989  PMID: 7035495

Abstract

The opsonophagocytic requirements of human sera containing endogenous complement for a variety of type Ia, and group B streptococcal strains were defined. Significant reduction (≧90%) in colony-forming units was noted after a 40-min incubation for the highly encapsulated, mouse-passed prototype strain 090 by sera containing moderate to high concentrations of antibody to type Ia polysaccharide (mean, 16.5 μg/ml), whereas bacterial growth occurred in 25 sera with low levels of specific antibody (mean, 2.1 μg/ml). This absolute requirement for a critical amount of specific antibody in promoting opsonophagocytic killing of strain 090 was not found when 18 fresh clinical type Ia isolates were tested. In antibody-deficient and agammaglobulinemic sera, respectively, mean reductions in colony-forming units of 94 and 95% were seen for fresh clinical isolates, whereas strain 090 was not killed by polymorphonuclear leukocytes in the presence of these sera. All strains required a considerable amount of specific antibody for alternative pathway-mediated opsonophagocytosis. That opsonophagocytic killing of clinical type Ia isolates was mediated by the classical pathway in a nonantibody-dependent fashion was shown when MgEGTA chelation of agammaglobulinemic serum or use of serum deficient in C2 resulted in bacterial growth. The addition of C2 to C2-deficient serum restored bactericidal activity of this serum. These experiments indicate that substances other than the exposed surface of the type Ia capsular polysaccharide initiate classical pathway-mediated opsonophagocytosis of clinical isolates of type Ia, group B streptococci by human sera in the absence of immunoglobulin. Perhaps, a deficiency in classical complement pathway function is critical to the susceptibility of neonates to type Ia, group B streptococcal disease.

Full text

PDF
394

Images in this article

399Image
on p.399

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baker C. J., Edwards M. S., Kasper D. L. Role of antibody to native type III polysaccharide of group B Streptococcus in infant infection. Pediatrics. 1981 Oct;68(4):544–549. [PubMed] [Google Scholar]
  2. Baker C. J. Group B streptococcal infections. Adv Intern Med. 1980;25:475–501. [PubMed] [Google Scholar]
  3. Baker C. J., Kasper D. L. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med. 1976 Apr 1;294(14):753–756. doi: 10.1056/NEJM197604012941404. [DOI] [PubMed] [Google Scholar]
  4. Baker C. J., Kasper D. L. Microcapsule of type III strains of group B Streptococcus: production and morphology. Infect Immun. 1976 Jan;13(1):189–194. doi: 10.1128/iai.13.1.189-194.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Baker C. J., Kasper D. L., Tager IRAB, Paredes A., Alpert S., McCormack W. M., Goroff D. Quantitative determination of antibody to capsular polysaccharide in infection with type III strains of group B Streptococcus. J Clin Invest. 1977 May;59(5):810–818. doi: 10.1172/JCI108703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Baker P. J., Stashak P. W., Prescott B. Use of erythrocytes sensitized with purified pneumococcal polysaccharides for the assay of antibody and antibody-producing cells. Appl Microbiol. 1969 Mar;17(3):422–426. doi: 10.1128/am.17.3.422-426.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Baltimore R. S., Baker C. J., Kasper D. L. Antibody to group B Streptococcus type III in human sera measured by a mouse protection test. Infect Immun. 1981 Apr;32(1):56–61. doi: 10.1128/iai.32.1.56-61.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Baltimore R. S., Kasper D. L., Vecchitto J. Mouse protection test for group B Streptococcus type III. J Infect Dis. 1979 Jul;140(1):81–88. doi: 10.1093/infdis/140.1.81. [DOI] [PubMed] [Google Scholar]
  9. Bartholomew R. M., Esser A. F. Mechanism of antibody-independent activation of the first component of complement (Cl) on retrovirus membranes. Biochemistry. 1980 Jun 24;19(13):2847–2853. doi: 10.1021/bi00554a005. [DOI] [PubMed] [Google Scholar]
  10. Clas F., Loos M. Antibody-independent binding of the first component of complement (C1) and its subcomponent C1q to the S and R forms of Salmonella minnesota. Infect Immun. 1981 Mar;31(3):1138–1144. doi: 10.1128/iai.31.3.1138-1144.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Davis C. A., Vallota E. H., Forristal J. Serum complement levels in infancy: age related changes. Pediatr Res. 1979 Sep;13(9):1043–1046. doi: 10.1203/00006450-197909000-00019. [DOI] [PubMed] [Google Scholar]
  12. Drew J. H., Arroyave C. M. The complement system of the newborn infant. Biol Neonate. 1980;37(3-4):209–217. doi: 10.1159/000241276. [DOI] [PubMed] [Google Scholar]
  13. Edwards M. S., Baker C. J., Kasper D. L. Opsonic specificity of human antibody to the type III polysaccharide of group B Streptococcus. J Infect Dis. 1979 Dec;140(6):1004–1008. doi: 10.1093/infdis/140.6.1004. [DOI] [PubMed] [Google Scholar]
  14. Edwards M. S., Nicholson-Weller A., Baker C. J., Kasper D. L. The role of specific antibody in alternative complement pathway-mediated opsonophagocytosis of type III, group B Streptococcus. J Exp Med. 1980 May 1;151(5):1275–1287. doi: 10.1084/jem.151.5.1275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Fischer G. W., Lowell G. H., Crumrine M. H., Bass J. W. Demonstration of opsonic activity and in vivo protection against group B streptococci type III by Streptococcus pneumoniae type 14 antisera. J Exp Med. 1978 Sep 1;148(3):776–786. doi: 10.1084/jem.148.3.776. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Fleming D. O. Mucin model for group B type III streptococcal infection in mice. Infect Immun. 1980 Feb;27(2):449–454. doi: 10.1128/iai.27.2.449-454.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Gotschlich E. C., Rey M., Triau R., Sparks K. J. Quantitative determination of the human immune response to immunization with meningococcal vaccines. J Clin Invest. 1972 Jan;51(1):89–96. doi: 10.1172/JCI106801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hemming V. G., Hall R. T., Rhodes P. G., Shigeoka A. O., Hill H. R. Assessment of group B streptococcal opsonins in human and rabbit serum by neutrophil chemiluminescence. J Clin Invest. 1976 Dec;58(6):1379–1387. doi: 10.1172/JCI108593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Jennings H. J., Rosell K. G., Kasper D. L. Structural determination and serology of the native polysaccharide antigen of type-III group B Streptococcus. Can J Biochem. 1980 Feb;58(2):112–120. doi: 10.1139/o80-016. [DOI] [PubMed] [Google Scholar]
  20. Jennings H. J., Rosell K. G., Kasper D. L. Structure and serology of the native polysaccharide antigen of type Ia group B streptococcus. Proc Natl Acad Sci U S A. 1980 May;77(5):2931–2935. doi: 10.1073/pnas.77.5.2931. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Kaplan M. H., Volanakis J. E. Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin. J Immunol. 1974 Jun;112(6):2135–2147. [PubMed] [Google Scholar]
  22. Kasper D. L., Baker C. J., Baltimore R. S., Crabb J. H., Schiffman G., Jennings H. J. Immunodeterminant specificity of human immunity to type III group B streptococcus. J Exp Med. 1979 Feb 1;149(2):327–339. doi: 10.1084/jem.149.2.327. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Kasper D. L., Baker C. J. Electron microscopic definition of surface antigens of group B Streptococcus. J Infect Dis. 1979 Feb;139(2):147–151. doi: 10.1093/infdis/139.2.147. [DOI] [PubMed] [Google Scholar]
  24. Koenig M. G., Melly M. A. The importance of surface antigens in staphylococcal virulence. Ann N Y Acad Sci. 1965 Jul 23;128(1):231–250. doi: 10.1111/j.1749-6632.1965.tb11641.x. [DOI] [PubMed] [Google Scholar]
  25. Lancefield R. C. A SEROLOGICAL DIFFERENTIATION OF SPECIFIC TYPES OF BOVINE HEMOLYTIC STREPTOCOCCI (GROUP B). J Exp Med. 1934 Mar 31;59(4):441–458. doi: 10.1084/jem.59.4.441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Lancefield R. C., Freimer E. H. Type-specific polysaccharide antigens of group B streptococci. J Hyg (Lond) 1966 Jun;64(2):191–203. doi: 10.1017/s0022172400040456. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Lancefield R. C., McCarty M., Everly W. N. Multiple mouse-protective antibodies directed against group B streptococci. Special reference to antibodies effective against protein antigens. J Exp Med. 1975 Jul 1;142(1):165–179. doi: 10.1084/jem.142.1.165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Lancefield R. C. TWO SEROLOGICAL TYPES OF GROUP B HEMOLYTIC STREPTOCOCCI WITH RELATED, BUT NOT IDENTICAL, TYPE-SPECIFIC SUBSTANCES. J Exp Med. 1938 Jan 1;67(1):25–40. doi: 10.1084/jem.67.1.25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Loos M., Wellek B., Thesen R., Opferkuch W. Antibody-independent interaction of the first component of complement with Gram-negative bacteria. Infect Immun. 1978 Oct;22(1):5–9. doi: 10.1128/iai.22.1.5-9.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. MacLEOD C. M., KRAUS M. R. Relation of virulence of pneumococcal strains for mice to the quantity of capsular polysaccharide formed in vitro. J Exp Med. 1950 Jul 1;92(1):1–9. doi: 10.1084/jem.92.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Mathews J. H., Klesius P. H., Zimmerman R. A. Opsonin system of the group B streptococcus. Infect Immun. 1974 Dec;10(6):1315–1320. doi: 10.1128/iai.10.6.1315-1320.1974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. McCARTY M., LANCEFIELD R. C. Variation in the group-specific carbohydrate of group A streptococci. I. Immunochemical studies on the carbohydrates of variant strains. J Exp Med. 1955 Jul 1;102(1):11–28. doi: 10.1084/jem.102.1.11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Nydegger U. E., Fearon D. T., Austen K. F. The modulation of the alternative pathway of complement in C2-deficient human serum by changes in concentration of the component and control proteins. J Immunol. 1978 Apr;120(4):1404–1408. [PubMed] [Google Scholar]
  34. Pittman M. VARIATION AND TYPE SPECIFICITY IN THE BACTERIAL SPECIES HEMOPHILUS INFLUENZAE. J Exp Med. 1931 Mar 31;53(4):471–492. doi: 10.1084/jem.53.4.471. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Raepple E., Hill H. U., Loos M. Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement--I. Effect on fluid phase C1 and on C1 bound to EA or to EAC4. Immunochemistry. 1976 Mar;13(3):251–255. doi: 10.1016/0019-2791(76)90223-8. [DOI] [PubMed] [Google Scholar]
  36. Stewardson-Krieger P. B., Albrandt K., Nevin T., Kretschmer R. R., Gotoff S. P. Perinatal immunity to group B beta-hemolytic streptococcus type Ia. J Infect Dis. 1977 Nov;136(5):649–654. doi: 10.1093/infdis/136.5.649. [DOI] [PubMed] [Google Scholar]
  37. Verbrugh H. A., Van Dijk W. C., Peters R., Van Der Tol M. E., Peterson P. K., Verhoef J. Staphylococcus aureus opsonization mediated via the classical and alternative complement pathways. A kinetic study using MgEGTA chelated serum and human sera deficient in IgG and complement factors C1s and C2. Immunology. 1979 Mar;36(3):391–397. [PMC free article] [PubMed] [Google Scholar]
  38. Verbrugh H. A., van Dijk W. C., Peters R., van Erne M. E., Daha M. R., Peterson P. K., Verhoef J. Opsonic recognition of staphylococci mediated by cell wall peptidoglycan: antibody-independent activation of human complement and opsonic activity of peptidoglycan antibodies. J Immunol. 1980 Mar;124(3):1167–1173. [PubMed] [Google Scholar]
  39. Verhoef J., Peterson P., Kim Y., Sabath L. D., Quie P. G. Opsonic requirements for staphylococcal phagocytosis. Heterogeneity among strains. Immunology. 1977 Aug;33(2):191–197. [PMC free article] [PubMed] [Google Scholar]
  40. Vogel L. C., Boyer K. M., Gotoff S. P., Kasper D. L., Baker C. J. Comparison of assays for antibody to group B Streptococcus, type III. J Infect Dis. 1980 Apr;141(4):530–530. doi: 10.1093/infdis/141.4.530. [DOI] [PubMed] [Google Scholar]
  41. Vogel L. C., Kretschmer R. R., Boyer K. M., Padnos D. M., Gadzala C. A., Gotoff S. P. Human immunity to group B streptococci measured by indirect immunofluorescence: correlation with protection in chick embryos. J Infect Dis. 1979 Nov;140(5):682–689. doi: 10.1093/infdis/140.5.682. [DOI] [PubMed] [Google Scholar]
  42. Ward H. K., Enders J. F. AN ANALYSIS OF THE OPSONIC AND TROPIC ACTION OF NORMAL AND IMMUNE SERA BASED ON EXPERIMENTS WITH THE PNEUMOCOCCUS. J Exp Med. 1933 Mar 31;57(4):527–547. doi: 10.1084/jem.57.4.527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Wilkinson H. W. Analysis of group B streptococcal types associated with disease in human infants and adults. J Clin Microbiol. 1978 Feb;7(2):176–179. doi: 10.1128/jcm.7.2.176-179.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES